Expert Point of View: Benefit of Panitumumab Seen Primarily in Patients with Recurrent or Metastatic Head and Neck Cancer and HPV-negative Tumors

Get Permission

Discussing the presentation, Jean Bourhis, MD, PhD, of the Institut Gustave Roussy in Villejuif, France, said that while HPV has become a major prognostic factor in locally advanced head and neck cancer, its prognostic value in recurrent and metastatic disease is less clear.

2.18.22_quote.jpg“The role of HPV in recurrent and metastatic disease for predicting response to EGFR monoclonal antibodies is also unknown,” he said.

According to Dr. Bourhis, SPECTRUM has several limitations. It is a subgroup and retrospective analysis, only two-thirds of the patients had HPV status evaluable, the analysis of HPV was primarily done on the primary (not the recurrent) tumor, and the test for interaction was nonsignificant. 

Nevertheless, this is the first description of EGFR inhibition activity specifically in HPV-negative disease, and the data are consistent with previous findings, he said.

“There is a potentially important clinical impact of these findings,” he concluded. “But because of some limitations in the study, there is a need for confirmation and for generating additional level 1 evidence in recurrent/metastatic disease.” ■

Disclosure: Dr. Bourhis reported no potential conflicts of interest.

Related Articles

Benefit of Panitumumab Seen Primarily in Patients with Recurrent or Metastatic Head and Neck Cancer

The addition of panitumumab (Vectibix) to chemotherapy improved overall and progression-free survival in patients with recurrent or metastatic squamous cell carcinoma of the head and neck, but its benefit was limited to patients whose tumors were negative for the human papillomavirus (HPV).1





By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.